$164.35
0.30% day before yesterday
Nasdaq, Jan 02, 10:05 pm CET

Repligen Corporation Stock price

$164.35
-0.67 0.41% 1M
+37.39 29.45% 6M
+0.49 0.30% YTD
+21.30 14.89% 1Y
-4.96 2.93% 3Y
-26.31 13.80% 5Y
+136.25 484.88% 10Y
+160.35 4,008.75% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
+0.49 0.30%

New AI Insights on Repligen Corporation Insights AI Insights on Repligen Corporation

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$9.3b
Enterprise Value
$9.0b
Net debt
positive
Cash
$748.8m
Shares outstanding
56.3m
Valuation (TTM | estimate)
P/E
5,478.3 | 96.7
P/S
13.1 | 12.4
EV/Sales
12.8 | 12.1
EV/FCF
84.9
P/B
4.4
Financial Health
Equity Ratio
69.7%
Return on Equity
-1.3%
ROCE
1.7%
ROIC
0.8%
Debt/Equity
0.3
Financials (TTM | estimate)
Revenue
$707.9m | $747.6m
EBITDA
$111.0m | $141.4m
EBIT
$46.6m | $90.2m
Net Income
$1.7m | $95.7m
Free Cash Flow
$106.5m
Growth (TTM | estimate)
Revenue
-8.5% | 17.8%
EBITDA
12.2% | 73.0%
EBIT
163.2% | 648.0%
Net Income
111.6% | 475.0%
Free Cash Flow
-18.9%
Margin (TTM | estimate)
Gross
51.6%
EBITDA
15.7% | 18.9%
EBIT
6.6%
Net
0.3% | 12.8%
Free Cash Flow
15.0%
More
EPS
$0.0
FCF per Share
$1.9
Short interest
9.9%
Employees
2k
Rev per Employee
$360.0k
Show more

Is Repligen Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Repligen Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

28 Analysts have issued a Repligen Corporation forecast:

23x Buy
82%
5x Hold
18%

Analyst Opinions

28 Analysts have issued a Repligen Corporation forecast:

Buy
82%
Hold
18%

Financial data from Repligen Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
708 708
9% 9%
100%
- Direct Costs 343 343
11% 11%
48%
365 365
6% 6%
52%
- Selling and Administrative Expenses 276 276
13% 13%
39%
- Research and Development Expense 52 52
1% 1%
7%
111 111
12% 12%
16%
- Depreciation and Amortization 64 64
21% 21%
9%
EBIT (Operating Income) EBIT 47 47
163% 163%
7%
Net Profit 1.74 1.74
112% 112%
0%

In millions USD.

Don't miss a Thing! We will send you all news about Repligen Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Repligen Corporation Stock News

Neutral
GlobeNewsWire
16 days ago
WALTHAM, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the J.P. Morgan 2026 Healthcare Conference, being held January 12 – 15 in San Francisco. Olivier Loeillot, President and Chief Executive Officer, will present an overview of the company on Tuesda...
Neutral
GlobeNewsWire
18 days ago
WALTHAM, Mass., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the launch of three new high-performance chromatography resins: AVIPure® HiPer™ AAV9 and AVIPure® HiPer™ AAV8 affinity resins, along with HiPer™ QA anion exchange resin, expanding the company's growing proteins portfolio an...
Neutral
Seeking Alpha
about one month ago
Repligen Corporation (RGEN) Presents at Evercore 8th Annual Healthcare Conference Transcript
More Repligen Corporation News

Company Profile

Repligen Corp. provides advanced bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. The firm serves through the following product lines: Chromatography; Filtration; and OEM Products (Proteins). The Chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs. The Filtration products offer a number of advantages to manufacturers of biologic drugs at volumes that span from pilot studies to clinical and commercial-scale production. The OEM products are represented by Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification, and cell culture growth factor products. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.

Head office United States
CEO Olivier Loeillot
Employees 1,778
Founded 1981
Website www.repligen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today